Copyright
©2014 Baishideng Publishing Group Co.
World J Anesthesiol. Mar 27, 2014; 3(1): 61-70
Published online Mar 27, 2014. doi: 10.5313/wja.v3.i1.61
Published online Mar 27, 2014. doi: 10.5313/wja.v3.i1.61
Name of assessment tool and type of study | Description | Who administers and time to administer | Interpretation of results | Validated | Sensitivity/specificity | Limitations | Intended use | Quality score[36] |
Substance abuse assessment tools | ||||||||
Drug abuse screening test[39] Prospective/ multiple studies | 28-item yes/no questionnaire to assess drug dependence or abuse (shorter versions of 10 or 20 items also available) | Patient; 5-10 min | A score of 6 or more indicates a drug abuse or dependence problem | Yes | 0.81-0.96/0.71-0.94 | Test and retest were only a few weeks apart (psychometrics may be falsely better), susceptible to patient deception. Also hasn’t been extensively tested in pain patients, therefore not specific to opioid use | For the initial assessment of drug abuse or dependence | N/A |
Risk assessment tools | ||||||||
Opioid risk tool[40] Prospective | A 5-domain checklist (family history of substance abuse, personal history of substance abuse, age, history of sexual abuse and psychological disease) gender stratified and weighted | Patient; < 2 min | Low risk 0-3 points Moderate risk 4-7 points High risk ≥ 8 points | Yes | c statistic for male model = 0.82 and female = 0.85 (both excellent discrimination) Sensitivity to detect discontinuance of opioids due to ADRB = 0.45[35] | Has only been validated in a pain clinic, therefore applicability outside this population is limited | To be used as a risk assessment tool for aberrant behaviors prior to initial opioid prescription | 4/9 |
Diagnosis, intractability, risk and efficacy inventory[41] Retrospective | 7 item questionnaire-4 domains (diagnosis, intractability, risk and efficacy) with the domain of risk divided into 4 subcategories (psychological, chemical health, reliability and social support) to determine if a patient is suitable for maintenance opioid therapy | Physician; < 2 min | Each questions is scored from 1 (least compelling/favorable) to 3 (most compelling/favorable) A score of ≤ 13 indicates an unsuitable candidate for maintenance opioid therapy A score of ≥ 14 indicates a good candidate with higher scores with a greater likelihood of successful prescription | Yes | Sensitivity to detect discontinuance of opioids due to ADRB = 0.45[35] Sensitivity to detect discontinuance of opioids due to ADRB = 0.17[35] To predict patient compliance = 0.94/0.87 | Used primary care vignettes versus real-time patients, small sample size (n = 61), drew upon patient cases in a referral centre (may not be generalizable), prospective validation needed | A decision tool to assess reliability of patients prescribed high risk therapy (opioids) in a primary care setting | N/A |
Screener and opioid assessment for patients with pain1[36,42,43] Prospective | 14-item questionnaire with answers scored on a likert 5-point scale of 0 (never) to 4 (very often) regarding drug history and other aberrant behaviors | Patient; < 5 min | A score of ≥ 8 indicates “high risk” of future aberrant drug related behaviors | Yes | Original Validation study 0.86/0.73 Sensitivity to detect likelihood of discontinuance of opioids due to ADRB = 0.72[35] | Predictive validity questionable as self-reported aberrant behaviors at baseline were compared to those at follow-up; also used PDUQ to identify/include higher-risk pain clinic participants (n = 175) | For the initial assessment of aberrant behaviors prior to initiating opioid therapy | 5/9 |
Screener and opioid assessment for patients with pain– revised1[34] Prospective | 24-item questionnaire with answers scored on a likert 5-point scale of 0 (never) to 4 (very often) regarding drug history and other aberrant behaviors | Patient; 2-5 min | Scores range from 0-96 Low risk < 18 points High risk ≥ 18 points | Yes | Original validation study 0.81/0.68 Ability to predict discharge from opioid treatment 0.39/0.69[33] Ability to predict presence of aberrant behaviors 0.41/0.71[33] | Has only been validated in a pain management clinic setting, less sensitive and specific than original SOAPP tool | For the initial assessment of aberrant behaviors prior to initiating opioid therapy | 6/9 |
Ongoing assessment tools (monitoring) | ||||||||
Addiction behaviors checklist1[44] Prospective cohort | 20-item yes/no questionnaire evaluating aberrant behaviors since last clinic visit and within current clinic visit | Physician; 5-10 min | A score of ≥ 3 “yes” answers indicates possible inappropriate opioid use and should alert physician to investigate further | Yes | 0.88/0.86 | Validation study conducted in predominantly male veterans and some high risk patients were excluded | A tool to assess previous and current/ongoing aberrant behaviors of patients on opioids | 4/9 |
Current opioid misuse measure1[45] Cross-sectional | 17-item questionnaire with answers scored on a Likert scale from 0 (never) to 4 (very often) assessing the frequency of aberrant behaviors in the previous 30 d | Patient; < 10 min | A cut-off score of ≥ 10 weakly increases the risk for ADRB | Yes | 0.74/0.73 | Has only been validated in a pain management centre, small follow-up sample size (n = 87), cross-validation studies are pending, limited evidence | To be used as a monitoring tool for aberrant behaviors in chronic pain patients | 5/9 |
Pain medication questionnaire[46,47] Cross-sectional Prospective cohort (long-term evaluation) | 26-item self-assessment questionnaire with answers scored on a Likert 5-point scale of 0 (disagree) to 4 (agree) | Patient; 5-10 min | Low risk 0-34 points High risk: 70-104 points High risk patients are associated with history of substance abuse, higher psychosocial distress and poorer functioning | Yes | None available | Has only been validated in a pain management clinic setting | An assessment tool for ongoing aberrant behaviors | 6/9 4/9 (long-term) |
Prescription drug use questionnaire1[31,48] Cross-sectional | 42-item yes/no questionnaire evaluating 6 domains: evaluation of pain condition, opioid use patterns, social/family factors, family history, history of substance abuse and psychiatric history | Physician; 15 min | Each “yes” answer counts as one point. A score of 15 or greater indicates a substance use disorder | Yes, but poor results | Cronbach’s coefficient for reliability α = 0.81 in original study with pain clinic patients but decreased to α = 0.56 in a general medical setting | Evaluates risk at a single time point, very lengthy/time consuming. Pain clinic patients only; designed to be administered by a mental health care practitioner. Performed poorly in a general medical population | A tool for addictive behaviors to be used in conjunction with other clinical criteria (DSM) to assess for the presence of addictive disease | 6-7/9 |
Prescription opioid therapy questionnaire1[49] Retrospective | Substance Abuse History Interview (3 questions) plus checklist of 6 aberrant behaviors | Physician; 2-5 min | Each item checked on substance abuse history equals one point 0-1 low risk 2-3 high risk | Yes | Sensitivity and specificity for each of the 6 aberrant behaviors determined[36] but some inconsistencies with original study | Limited to a pain clinic population, developed using retrospective chart review | A screening tool to identify substance abuse history and ongoing aberrant behaviors | 7/92 |
Documentation tools | ||||||||
Patient assessment and documentation tool1[50] Cross-sectional (field tested) | A 41-item clinician-directed interview chart note tool divided into 4 domains (4 A's): analgesia, activities of daily living, adverse events and aberrant drug-related behaviors | Physician; 10-15 min | A descriptive tool to aid in documentation (chart note) | Field-tested, but not validated | N/A | Descriptive tool; validation needed (no sensitivity or specificity data available) | A documentation tool to organize chart note information related to opioid use | N/A |
- Citation: Frankel GE, Intrater H, Doupe M, Namaka M. Opioid misuse in Canada and critical appraisal of aberrant behavior screening tools. World J Anesthesiol 2014; 3(1): 61-70
- URL: https://www.wjgnet.com/2218-6182/full/v3/i1/61.htm
- DOI: https://dx.doi.org/10.5313/wja.v3.i1.61